GE GEHC GE HealthCare Technologies Inc. Common Stock Загрузка... : Бычьи и медвежьи мнения аналитиков

JP Morgan, TD Cowen, RBC, Jefferies, Piper

GE HealthCare's post-earnings jump and reaffirmed guidance reflect a neutral hold rating.

GE HealthCare CEO Peter Arduini reported 11% orders growth driven by broad-based execution.

Management maintains full-year guidance and expresses confidence in medium-term targets, underpinned by robust order growth (11%) and a strong product pipeline, although a soft PCS segment remains a short-term drag.

Premarket movers include Avantor rising 4% on earnings beat.

US pre-market movers report shows mixed earnings reactions with Meta and Microsoft slightly.

GE Healthcare reported Q2 2026 adjusted EPS of $1.13 beating estimates and reaffirmed its.

GE Healthcare beats Q2 2026 earnings estimates on adjusted EPS, EBIT.

GE Healthcare reported preliminary Q2 revenue above expectations.

GE Healthcare reports preliminary Q2 2026 revenue of 5.30 billion dollars beating estimates.

BMO initiates coverage on GE HealthCare with a Market Perform rating and a target price of $70.

Long medtech and digital health names as rising semiconductor content in medical devices drives.

Long medical imaging hardware suppliers as improving MRI component demand signals a recovery.

GEHC laggard observation; no explicit trade call.

Bearish view on GEHC on the view that semiconductor memory cost inflation will hit margins.

Guidance was lowered due to significant raw material cost inflation (memory, oil, freight), which will pressure profit through the year, partly offset by price actions.

The tweet suggests portfolio managers have built careers betting against Jay Saccaro's.

GE HealthCare trades at 16x earnings, while its medtech peers trade at 29-37x. The company has a $21.8B order backlog and is pivoting to higher-margin AI diagnostics and recurring software revenue. The market misclassifies GEHC as a cyclical equipment maker, failing to recognize its transformation into a higher-growth, higher-margin medtech company. This misperception creates a significant valuation gap. The stock offers a compelling opportunity for multiple expansion as the market recognizes its successful pivot to AI and software, supported by a strong backlog and clear growth path. The pivot to AI and software may be slower or less profitable than anticipated; competition in the medtech space could intensify; hospital capital expenditure could slow down.

Watch GEHC on rising diagnostic imaging demand.

Management tone is confident, reflected in initiating FY2026 guidance for EPS growth and margin expansion despite conservative China outlook, pointing to stronger 2027.

Quest's Alzheimer's blood test (AD-Detect) revenue more than doubled in Q3 following new clinical guidelines, signaling rapid market adoption and potential pressure on amyloid PET and CSF testing. — Blood-based biomarkers are displacing more expensive imaging and CSF tests, which could reduce volumes for PET tracer suppliers and CSF assay platforms.